Researchers at Xi’an Jiaotong-Liverpool University and Nanjing University have developed a novel nanoparticle drug delivery system combining PLGA polymer with albumin protein, yielding supraparticles with ultrahigh colloidal stability and drug loading capacity. This hybrid system encapsulates up to 40% weight of doxorubicin, significantly surpassing conventional formulations. In vitro and in vivo studies demonstrate enhanced stability and reduced side effects. The approach addresses longstanding challenges in sustained drug release and nanoparticle aggregation, potentially improving chemotherapy efficacy and patient tolerance across oncology and related therapeutic areas.